戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 enol red-free media or in the presence of an estrogen receptor antagonist.
2 ot blocked by ICI182780 (50 micro mol/L), an estrogen receptor antagonist.
3                   Fulvestrant is a selective estrogen receptor antagonist.
4   This protective effect was abrogated by an estrogen-receptor antagonist.
5 ive effect of E2 was nullified by a specific estrogen-receptor antagonist.
6 mented estrogenic responses not inhibited by estrogen receptor antagonists.
7                               The endogenous estrogen receptor antagonist 27-hydroxycholesterol (27OH
8                                              Estrogen receptor antagonists 4-hydroxytamoxifen and 7al
9 he presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the
10 bited through light-dependent release of the estrogen receptor antagonist, 4-hydroxycyclofen.
11 eliminated by ICI 182,780 (10(-7) mol/L), an estrogen receptor antagonist; 5, 6-dichloro-1-beta-D-rib
12 estrogen receptor because addition of a pure estrogen receptor antagonist abrogated this effect.
13  AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER(+)
14 ential chemopreventive activity of selective estrogen-receptor antagonists as chemopreventives for br
15                                              Estrogen receptor antagonists blocked the synergistic in
16  Topical treatments with ICI 182,780, a pure estrogen receptor antagonist, caused the hair follicles
17 ral selective ER degraders (SERDs), complete estrogen receptor antagonists (CERANs), selective estrog
18 ale AVP(PVN) neuronal numbers, whereas a pan-estrogen receptor antagonist exposed from E13.5 to E15.5
19 trogen receptor modulator that is used as an estrogen receptor antagonist for the treatment and preve
20                                Moreover, the estrogen receptor antagonist fulvestrant (ICI 182,780) d
21               This effect was blocked by the estrogen receptor antagonist fulvestrant (ICI-182,780, F
22 ): androgen receptor antagonist (flutamide); estrogen receptor antagonist (fulvestrant); TES suppleme
23 d small effects on cAMP levels but G protein estrogen receptor antagonists had little effect on respo
24 revent masculine development through various estrogen receptor antagonists have been relatively ineff
25                                          The estrogen receptor antagonist ICI 164384 had no effect on
26  the PI3-kinase inhibitor, LY294002, and the estrogen receptor antagonist ICI 182, 780.
27          These effects were inhibited by the estrogen receptor antagonist ICI 182,780 but could be pr
28      In vitro, concurrent treatment with the estrogen receptor antagonist ICI 182,780 rescued TH-ir c
29 s of estradiol are completely blocked by the estrogen receptor antagonist ICI 182,780, and the intrac
30 variectomized mice, and was prevented by the estrogen receptor antagonist ICI 182,780.
31 echol estrogens, but not by 17beta-E2 or the estrogen receptor antagonist ICI 182,780.
32 ability, an effect partially reversed by the estrogen receptor antagonist ICI 182,780.
33 and completely inhibited by the conventional estrogen receptor antagonist ICI 182,780.
34 f wild-type cultures, was not blocked by the estrogen receptor antagonist ICI 182,780.
35 ibited by the antiestrogen tamoxifen and the estrogen receptor antagonist ICI 182,780.
36 nificantly attenuated in the presence of the estrogen receptor antagonist ICI-182780.
37 retreatment with indomethacin or the classic estrogen-receptor antagonist ICI 182,780 did not alter t
38 oprotective effects of E2 were blocked by an estrogen receptor antagonist (ICI 182,780) and by a Trx
39                 Estrogen, with or without an estrogen receptor antagonist (ICI 182,780), a PI3K inhib
40 diol-BSA; 1 mg/kg estradiol) with or without estrogen receptor antagonist (ICI 182,780), PI3K inhibit
41 pansion in culture was blocked by a specific estrogen receptor antagonist (ICI 182,780).
42                                          The estrogen receptor antagonist, ICI 182,780, did not block
43               This effect was blocked by the estrogen receptor antagonist, ICI 182,780, indicating th
44 e estrogen receptor, and the addition of the estrogen receptor antagonist, ICI 182,780, to influence
45 H was not antagonized by the addition of the estrogen receptor antagonist, ICI 182,780.
46                                           An estrogen receptor antagonist, ICI-182,780, or E2 failed
47 ression was inhibited in the presence of the estrogen receptor antagonist, ICI-182780.
48        Inhibiting estrogen activity using an estrogen receptor antagonist, ICI182,780 (ICI), and/or E
49                  We observed that a specific estrogen receptor antagonist (ICI182780) was able to pre
50 port the hypothesis that ICI is an effective estrogen receptor antagonist in the zebra finch brain an
51  ovariectomy or treating female mice with an estrogen receptor antagonist increased mortality, indica
52 ce was eliminated after pretreatment with an estrogen receptor antagonist or ovariectomy but restored
53  single intracerebroventricular injection of estrogen receptor antagonists or aromatase inhibitors, r
54 vessels with 17beta-E2 plus ICI, 182,780, an estrogen receptor antagonist, or wortmannin, an inhibito
55 eptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppre
56                              Addition of the estrogen receptor antagonist tamoxifen did not reverse t
57                Elacestrant is the first oral estrogen receptor antagonist to receive FDA approval for
58 at were previously reported as non-steroidal estrogen receptor antagonists with in vitro and in vivo
59 xifen and in designing screens to select for estrogen-receptor antagonists without these side effects
60 ion; this effect was blocked by the specific estrogen receptor antagonist ZK-119.010.